462 is the total number of securities Baker Brothers Advisors has owned. The longest Baker Brothers Advisors has owned a single stock is 42 quarters.
Period | Weighting | Quarter | |||||||
---|---|---|---|---|---|---|---|---|---|
Ticker | Name | Longest | Shortest | Min. | Avg. | Max. | First | Latest | ↓ Count |
INCY | Incyte Corporation | 42 | 42 | 6.44% | 16.38% | 37.57% | Q2 2013 | Q3 2023 | 42 |
ACAD | ACADIA Pharmaceuticals... | 42 | 42 | 3.06% | 6.36% | 10.90% | Q2 2013 | Q3 2023 | 42 |
BMRN | Biomarin Pharmaceutica... | 42 | 42 | 0.80% | 3.47% | 5.86% | Q2 2013 | Q3 2023 | 42 |
BCRX | BioCryst Pharmaceutica... | 42 | 42 | 0.14% | 0.72% | 1.70% | Q2 2013 | Q3 2023 | 42 |
CERS | Cerus Corporation | 42 | 42 | 0.16% | 0.48% | 0.89% | Q2 2013 | Q3 2023 | 42 |
INSM | Insmed Incorporated | 42 | 42 | 0.00% | 0.20% | 0.43% | Q2 2013 | Q3 2023 | 42 |
MRTX | Mirati Therapeutics, Inc. | 41 | 41 | 0.07% | 0.65% | 1.76% | Q3 2013 | Q3 2023 | 41 |
BLUE | Bluebird Bio Inc. | 41 | 41 | 0.01% | 0.11% | 0.31% | Q3 2013 | Q3 2023 | 41 |
HRTX | Heron Therapeutics, Inc. | 39 | 39 | 0.05% | 0.49% | 1.47% | Q1 2014 | Q3 2023 | 39 |
CCXI | ChemoCentryx, Inc. | 32 | 5 | 0.00% | 0.07% | 0.61% | Q2 2013 | Q3 2022 | 37 |
AFMD | Affimed Therapeutics B.V. | 37 | 37 | 0.00% | 0.02% | 0.13% | Q3 2014 | Q3 2023 | 37 |
DBVT | DBV Technologies S.A. | 36 | 36 | 0.10% | 0.73% | 1.90% | Q4 2014 | Q3 2023 | 36 |
NVTA | Invitae Corporation | 35 | 35 | 0.01% | 0.76% | 2.61% | Q1 2015 | Q3 2023 | 35 |
XNCR | Xencor, Inc. | 30 | 4 | 0.01% | 0.11% | 0.24% | Q4 2013 | Q3 2023 | 34 |
NBIX | Neurocrine Biosciences... | 33 | 33 | 0.09% | 0.40% | 0.87% | Q1 2014 | Q1 2022 | 33 |
ASND | Ascendis Pharma SA | 32 | 32 | 0.01% | 1.58% | 3.63% | Q1 2015 | Q4 2022 | 32 |
BGNE | BeiGene, Ltd. | 31 | 31 | 0.54% | 9.77% | 18.60% | Q1 2016 | Q3 2023 | 31 |
AMRN | Amarin Corp. PLC | 31 | 31 | 0.01% | 1.25% | 5.74% | Q1 2015 | Q3 2022 | 31 |
SGMO | Sangamo Therapeutics, ... | 31 | 31 | 0.02% | 0.15% | 0.32% | Q3 2013 | Q1 2021 | 31 |
MGNX | MacroGenics, Inc. | 19 | 1 | 0.02% | 0.06% | 0.11% | Q4 2013 | Q2 2023 | 31 |
XLRN | Acceleron Pharma, Inc. | 24 | 7 | 0.01% | 0.02% | 0.06% | Q4 2013 | Q3 2021 | 31 |
SGEN | Seattle Genetics, Inc. | 29 | 29 | 8.49% | 19.53% | 35.57% | Q2 2013 | Q2 2020 | 29 |
MDGL | Madrigal Pharmaceutica... | 29 | 29 | 0.01% | 0.85% | 2.69% | Q3 2016 | Q3 2023 | 29 |
AGLE | Aeglea BioTherapeutics... | 29 | 29 | 0.01% | 0.07% | 0.18% | Q2 2016 | Q2 2023 | 29 |
ALKS | Alkermes PLC | 28 | 28 | 0.02% | 0.10% | 0.25% | Q4 2015 | Q3 2022 | 28 |
ADAP | Adaptimmune Therapeuti... | 15 | 13 | 0.00% | 0.08% | 0.30% | Q2 2015 | Q3 2023 | 28 |
CPRX | Catalyst Pharmaceutica... | 27 | 27 | 0.01% | 0.10% | 0.28% | Q1 2014 | Q3 2020 | 27 |
ANAB | AnaptysBio, Inc. | 27 | 27 | 0.01% | 0.06% | 0.16% | Q1 2017 | Q3 2023 | 27 |
GHDX | Genomic Health, Inc. | 26 | 26 | 2.67% | 4.46% | 8.56% | Q2 2013 | Q3 2019 | 26 |
ARGX | argenx SE | 26 | 26 | 0.02% | 0.93% | 2.41% | Q2 2017 | Q3 2023 | 26 |
HALO | Halozyme Therapeutics,... | 26 | 26 | 0.03% | 0.33% | 1.33% | Q2 2013 | Q3 2019 | 26 |
RARE | Ultragenyx Pharmaceuti... | 14 | 12 | 0.01% | 0.12% | 0.28% | Q1 2014 | Q3 2023 | 26 |
ACHN | Achillion Pharmaceutic... | 26 | 26 | 0.01% | 0.07% | 0.20% | Q2 2013 | Q3 2019 | 26 |
ASMB | Assembly Biosciences, ... | 26 | 26 | 0.01% | 0.06% | 0.17% | Q1 2015 | Q2 2021 | 26 |
ARRY | Array BioPharma Inc. | 25 | 25 | 0.06% | 0.32% | 0.90% | Q2 2013 | Q2 2019 | 25 |
MRUS | Merus N.V. | 25 | 25 | 0.09% | 0.17% | 0.32% | Q2 2016 | Q2 2022 | 25 |
KRYS | Krystal Biotech, Inc. | 25 | 25 | 0.01% | 0.16% | 0.31% | Q3 2017 | Q3 2023 | 25 |
QURE | UniQure N.V. | 13 | 12 | 0.00% | 0.07% | 0.28% | Q1 2014 | Q4 2020 | 25 |
FLGT | Fulgent Genetics, Inc. | 25 | 25 | 0.00% | 0.05% | 0.17% | Q3 2016 | Q3 2022 | 25 |
INFI | Infinity Pharmaceutica... | 18 | 2 | 0.00% | 0.04% | 0.33% | Q2 2013 | Q4 2020 | 25 |
ALXN | Alexion Pharmaceutical... | 24 | 24 | 2.65% | 7.24% | 10.37% | Q2 2015 | Q1 2021 | 24 |
RYTM | Rhythm Pharmaceuticals... | 24 | 24 | 0.10% | 0.45% | 1.11% | Q4 2017 | Q3 2023 | 24 |
GLPG | Galapagos NV ADR | 24 | 24 | 0.00% | 0.11% | 0.22% | Q2 2015 | Q1 2021 | 24 |
CBAY | CymaBay Therapeutics, ... | 12 | 11 | 0.01% | 0.16% | 0.50% | Q4 2016 | Q4 2022 | 23 |
LJPC | La Jolla Pharmaceutica... | 23 | 23 | 0.00% | 0.05% | 0.13% | Q1 2014 | Q3 2019 | 23 |
AQXP | Aquinox Pharmaceutical... | 22 | 22 | 0.07% | 0.64% | 1.70% | Q1 2014 | Q2 2019 | 22 |
KNSA | Kiniksa Pharmaceutical... | 22 | 22 | 0.14% | 0.26% | 0.69% | Q2 2018 | Q3 2023 | 22 |
BDSI | BioDelivery Sciences I... | 21 | 1 | 0.00% | 0.02% | 0.07% | Q2 2013 | Q1 2020 | 22 |
BLCM | Bellicum Pharmaceutica... | 21 | 21 | 0.02% | 0.44% | 1.01% | Q4 2014 | Q4 2019 | 21 |
PGNX | Progenics Pharmaceutic... | 21 | 21 | 0.06% | 0.23% | 0.37% | Q2 2013 | Q2 2018 | 21 |
FOMX | Foamix Pharmaceuticals... | 21 | 21 | 0.01% | 0.10% | 0.27% | Q3 2014 | Q3 2019 | 21 |
STML | Stemline Therapeutics,... | 21 | 21 | 0.01% | 0.09% | 0.52% | Q2 2013 | Q2 2018 | 21 |
SYRS | Syros Pharmaceuticals,... | 21 | 21 | 0.00% | 0.04% | 0.08% | Q2 2016 | Q2 2021 | 21 |
EPZM | Epizyme, Inc. | 19 | 2 | 0.01% | 0.03% | 0.08% | Q2 2013 | Q2 2022 | 21 |
ADMS | Adamas Pharmaceuticals... | 21 | 21 | 0.00% | 0.02% | 0.05% | Q1 2016 | Q1 2021 | 21 |
CYCCP | Cyclacel Pharmaceutica... | 21 | 21 | 0.00% | 0.00% | 0.00% | Q2 2013 | Q2 2018 | 21 |
KOD | Kodiak Sciences, Inc. | 20 | 20 | 0.18% | 2.65% | 7.68% | Q4 2018 | Q3 2023 | 20 |
IDRA | Idera Pharmaceuticals,... | 20 | 20 | 0.05% | 0.18% | 0.60% | Q2 2013 | Q1 2018 | 20 |
AIMT | Aimmune Therapeutics, ... | 20 | 20 | 0.04% | 0.11% | 0.22% | Q3 2015 | Q2 2020 | 20 |
ONCE | Spark Therapeutics, Inc. | 19 | 19 | 0.39% | 0.63% | 1.00% | Q1 2015 | Q3 2019 | 19 |
ACOR | Acorda Therapeutics, Inc. | 13 | 1 | 0.02% | 0.40% | 1.27% | Q1 2014 | Q3 2019 | 19 |
Biomarin Pharmaceutica... | 19 | 19 | 0.10% | 0.14% | 0.19% | Q4 2013 | Q2 2018 | 19 | |
NTLA | Intellia Therapeutics,... | 19 | 19 | 0.01% | 0.09% | 0.24% | Q2 2016 | Q4 2020 | 19 |
AERI | Aerie Pharmaceuticals,... | 19 | 19 | 0.03% | 0.08% | 0.16% | Q4 2013 | Q2 2018 | 19 |
ALBO | Albireo Pharma, Inc. | 19 | 19 | 0.01% | 0.05% | 0.07% | Q2 2017 | Q4 2021 | 19 |
VSAR | Versartis, Inc. | 18 | 18 | 0.02% | 0.26% | 0.52% | Q2 2014 | Q3 2018 | 18 |
ZYME | Zymeworks Inc. | 18 | 18 | 0.05% | 0.22% | 0.41% | Q2 2018 | Q3 2022 | 18 |
BCEL | Atreca, Inc. | 18 | 18 | 0.01% | 0.16% | 0.45% | Q2 2019 | Q3 2023 | 18 |
AGIO | Agios Pharmaceuticals,... | 18 | 18 | 0.05% | 0.09% | 0.19% | Q3 2013 | Q4 2017 | 18 |
NVAX | Novavax, Inc. | 12 | 2 | 0.02% | 0.09% | 0.19% | Q3 2013 | Q4 2018 | 18 |
HOOK | HOOKIPA Pharma Inc. | 18 | 18 | 0.01% | 0.03% | 0.06% | Q2 2019 | Q3 2023 | 18 |
NTRA | Natera, Inc. | 12 | 6 | 0.02% | 0.03% | 0.06% | Q3 2015 | Q3 2023 | 18 |
Trillium Therapeutics,... | 18 | 18 | 0.00% | 0.02% | 0.06% | Q3 2015 | Q4 2019 | 18 | |
DVAX | Dynavax Technologies C... | 18 | 18 | 0.00% | 0.01% | 0.02% | Q3 2015 | Q4 2019 | 18 |
FPRX | Five Prime Therapeutic... | 17 | 1 | 0.00% | 0.01% | 0.04% | Q4 2013 | Q4 2020 | 18 |
IGMS | IGM Biosciences, Inc. | 17 | 17 | 0.15% | 0.64% | 1.15% | Q3 2019 | Q3 2023 | 17 |
MYOK | MyoKardia, Inc. | 17 | 17 | 0.01% | 0.37% | 1.64% | Q3 2016 | Q3 2020 | 17 |
SAGE | Sage Therapeutics, Inc. | 17 | 17 | 0.03% | 0.24% | 0.88% | Q3 2014 | Q3 2018 | 17 |
TCDA | Tricida, Inc. | 9 | 8 | 0.01% | 0.21% | 0.53% | Q2 2018 | Q3 2022 | 17 |
GWPH | GW Pharmaceuticals PLC | 14 | 1 | 0.01% | 0.21% | 0.46% | Q4 2013 | Q4 2020 | 17 |
CRNX | Crinetics Pharmaceutic... | 17 | 17 | 0.02% | 0.05% | 0.11% | Q3 2018 | Q3 2022 | 17 |
KPTI | Karyopharm Therapeutic... | 17 | 17 | 0.02% | 0.03% | 0.06% | Q4 2013 | Q4 2017 | 17 |
PRTO | Proteon Therapeutics, ... | 17 | 17 | 0.00% | 0.02% | 0.04% | Q4 2014 | Q4 2018 | 17 |
MDWD | MediWound Ltd. | 17 | 17 | 0.01% | 0.01% | 0.03% | Q2 2014 | Q2 2018 | 17 |
SNSS | Sunesis Pharmaceutical... | 17 | 17 | 0.00% | 0.01% | 0.03% | Q3 2016 | Q3 2020 | 17 |
Biomarin Pharmaceutica... | 16 | 16 | 0.78% | 1.02% | 1.32% | Q2 2013 | Q1 2017 | 16 | |
AKAOQ | Achaogen, Inc. | 16 | 16 | 0.00% | 0.19% | 0.95% | Q1 2014 | Q4 2017 | 16 |
NLTX | Neoleukin Therapeutics... | 16 | 16 | 0.01% | 0.13% | 0.25% | Q3 2019 | Q2 2023 | 16 |
ABEO | Abeona Therapeutics Inc. | 16 | 16 | 0.01% | 0.11% | 0.27% | Q3 2016 | Q2 2020 | 16 |
BioMarin Pharmaceutica... | 12 | 4 | 0.02% | 0.09% | 0.13% | Q3 2017 | Q3 2021 | 16 | |
RXDX | Ignyta, Inc. | 16 | 16 | 0.03% | 0.07% | 0.32% | Q1 2014 | Q4 2017 | 16 |
LGND | Ligand Pharmaceuticals... | 16 | 16 | 0.04% | 0.07% | 0.09% | Q1 2014 | Q4 2017 | 16 |
AUPH | Aurinia Pharmaceutical... | 8 | 8 | 0.02% | 0.06% | 0.18% | Q3 2014 | Q3 2021 | 16 |
CABA | Cabaletta Bio, Inc. | 16 | 16 | 0.00% | 0.04% | 0.14% | Q4 2019 | Q3 2023 | 16 |
DSCI | Derma Sciences, Inc. | 15 | 15 | 0.12% | 0.29% | 0.57% | Q2 2013 | Q4 2016 | 15 |
DNLI | Denali Therapeutics Inc. | 15 | 15 | 0.01% | 0.08% | 0.27% | Q1 2020 | Q3 2023 | 15 |
ENTA | Enanta Pharmaceuticals... | 15 | 15 | 0.02% | 0.03% | 0.04% | Q2 2013 | Q4 2016 | 15 |
ALEC | Alector, Inc. | 15 | 15 | 0.01% | 0.03% | 0.04% | Q1 2020 | Q3 2023 | 15 |
MTEM | Molecular Templates, Inc. | 15 | 15 | 0.00% | 0.01% | 0.02% | Q3 2017 | Q1 2021 | 15 |
LPTX | Leap Therapeutics, Inc. | 15 | 15 | 0.00% | 0.01% | 0.01% | Q3 2019 | Q1 2023 | 15 |
BTXWS | BioTime, Inc. Rights | 15 | 15 | 0.00% | 0.00% | 0.00% | Q4 2014 | Q2 2018 | 15 |
Acorda Therapeutics No... | 14 | 14 | 0.24% | 0.49% | 0.78% | Q3 2014 | Q4 2017 | 14 | |
GBT | Global Blood Therapeut... | 11 | 3 | 0.01% | 0.40% | 1.66% | Q3 2015 | Q3 2022 | 14 |
REPL | Replimune Group, Inc. | 14 | 14 | 0.00% | 0.24% | 0.75% | Q2 2020 | Q3 2023 | 14 |
RARX | Ra Pharmaceuticals, Inc. | 14 | 14 | 0.01% | 0.16% | 0.62% | Q4 2016 | Q1 2020 | 14 |
XENE | Xenon Pharmaceuticals ... | 14 | 14 | 0.03% | 0.11% | 0.18% | Q2 2020 | Q3 2023 | 14 |
OSIR | Osiris Therapeutics, Inc. | 14 | 14 | 0.02% | 0.06% | 0.10% | Q3 2013 | Q4 2016 | 14 |
RIGL | Rigel Pharmaceuticals,... | 7 | 7 | 0.01% | 0.04% | 0.08% | Q3 2013 | Q2 2018 | 14 |
CLLS | Cellectis SA | 14 | 14 | 0.01% | 0.01% | 0.02% | Q1 2015 | Q2 2018 | 14 |
TARA | Protara Therapeutics, ... | 14 | 14 | 0.00% | 0.01% | 0.03% | Q2 2020 | Q3 2023 | 14 |
SGEN | Seagen Inc. | 13 | 13 | 28.46% | 39.99% | 54.48% | Q3 2020 | Q3 2023 | 13 |
Incyte Genomics Notes... | 13 | 13 | 4.21% | 4.74% | 5.53% | Q4 2013 | Q4 2016 | 13 | |
Incyte Genomics Notes... | 13 | 13 | 3.88% | 4.40% | 5.17% | Q4 2013 | Q4 2016 | 13 | |
PRLD | Prelude Therapeutics I... | 13 | 13 | 0.18% | 0.88% | 2.73% | Q3 2020 | Q3 2023 | 13 |
KYMR | Kymera Therapeutics, Inc. | 13 | 13 | 0.25% | 0.46% | 0.74% | Q3 2020 | Q3 2023 | 13 |
VNDA | Vanda Pharmaceuticals,... | 9 | 4 | 0.04% | 0.44% | 0.92% | Q2 2013 | Q2 2018 | 13 |
NRIX | Nurix Therapeutics, Inc. | 13 | 13 | 0.18% | 0.26% | 0.35% | Q3 2020 | Q3 2023 | 13 |
XNPT | XenoPort, Inc. | 13 | 13 | 0.08% | 0.26% | 0.62% | Q2 2013 | Q2 2016 | 13 |
PACB | Pacific Biosciences of... | 13 | 13 | 0.04% | 0.25% | 0.61% | Q3 2020 | Q3 2023 | 13 |
AKRO | Akero Therapeutics, Inc. | 13 | 13 | 0.01% | 0.25% | 0.78% | Q3 2020 | Q3 2023 | 13 |
IMTX | Immatics N.V. | 13 | 13 | 0.04% | 0.23% | 0.38% | Q3 2020 | Q3 2023 | 13 |
AXSM | Axsome Therapeutics, Inc. | 13 | 13 | 0.08% | 0.20% | 0.46% | Q1 2019 | Q1 2022 | 13 |
TGTX | TG Therapeutics, Inc. | 13 | 13 | 0.04% | 0.20% | 0.33% | Q3 2013 | Q3 2016 | 13 |
IMGN | ImmunoGen, Inc. | 12 | 1 | 0.06% | 0.20% | 0.50% | Q1 2015 | Q2 2023 | 13 |
ALLK | Allakos Inc. | 13 | 13 | 0.01% | 0.19% | 0.38% | Q3 2019 | Q3 2022 | 13 |
APLS | Apellis Pharmaceutical... | 13 | 13 | 0.02% | 0.14% | 0.63% | Q2 2018 | Q2 2021 | 13 |
DERM | Dermira, Inc. | 10 | 3 | 0.01% | 0.06% | 0.12% | Q4 2014 | Q3 2019 | 13 |
RETA | Reata Pharmaceuticals,... | 13 | 13 | 0.02% | 0.06% | 0.14% | Q4 2019 | Q4 2022 | 13 |
ATHA | Athira Pharma, Inc. | 13 | 13 | 0.02% | 0.05% | 0.10% | Q3 2020 | Q3 2023 | 13 |
LOXO | Loxo Oncology, Inc. | 13 | 13 | 0.01% | 0.04% | 0.10% | Q3 2014 | Q3 2017 | 13 |
IFRX | InflaRx N.V. | 7 | 6 | 0.00% | 0.03% | 0.06% | Q4 2017 | Q1 2021 | 13 |
SBPH | Spring Bank Pharmaceut... | 13 | 13 | 0.01% | 0.03% | 0.05% | Q4 2016 | Q4 2019 | 13 |
Protalix BioTherapeuti... | 13 | 13 | 0.02% | 0.02% | 0.03% | Q4 2014 | Q4 2017 | 13 | |
NGM | NGM Biopharmaceuticals... | 13 | 13 | 0.00% | 0.02% | 0.04% | Q2 2019 | Q2 2022 | 13 |
ITOS | Iteos Therapeutics, Inc. | 13 | 13 | 0.01% | 0.02% | 0.03% | Q3 2020 | Q3 2023 | 13 |
GTH | Genetron Holdings Limited | 13 | 13 | 0.00% | 0.01% | 0.04% | Q3 2020 | Q3 2023 | 13 |
Bellicum Pharmaceutica... | 13 | 13 | 0.00% | 0.00% | 0.01% | Q1 2020 | Q1 2023 | 13 | |
Gilead Sciences, Inc. ... | 12 | 12 | 0.75% | 0.92% | 1.26% | Q2 2013 | Q1 2016 | 12 | |
ABCL | AbCellera Biologics Inc. | 12 | 12 | 0.43% | 0.83% | 1.58% | Q4 2020 | Q3 2023 | 12 |
HZNP | Horizon Therapeutics P... | 12 | 12 | 0.04% | 0.31% | 0.66% | Q1 2020 | Q4 2022 | 12 |
ITCI | Intra-Cellular Therapi... | 12 | 12 | 0.02% | 0.12% | 0.27% | Q1 2015 | Q4 2017 | 12 |
Aegerion Pharmaceutica... | 12 | 12 | 0.04% | 0.12% | 0.19% | Q3 2015 | Q2 2018 | 12 | |
IDRA | Idera Pharmaceuticals,... | 12 | 12 | 0.01% | 0.11% | 0.38% | Q2 2018 | Q1 2021 | 12 |
OPT | Opthea Limited | 12 | 12 | 0.03% | 0.10% | 0.14% | Q4 2020 | Q3 2023 | 12 |
NeuroDerm Ltd. | 12 | 12 | 0.03% | 0.08% | 0.18% | Q4 2014 | Q3 2017 | 12 | |
ALGS | Aligos Therapeutics, Inc. | 12 | 12 | 0.01% | 0.07% | 0.17% | Q4 2020 | Q3 2023 | 12 |
IRWD | Ironwood Pharmaceutica... | 12 | 12 | 0.02% | 0.06% | 0.18% | Q2 2013 | Q1 2016 | 12 |
AKTX | Akari Therapeutics PLC... | 12 | 12 | 0.00% | 0.04% | 0.09% | Q3 2015 | Q2 2018 | 12 |
CYTR | CytRx Corporation | 11 | 1 | 0.00% | 0.03% | 0.07% | Q2 2013 | Q3 2016 | 12 |
AUTL | Autolus Therapeutics plc | 12 | 12 | 0.01% | 0.03% | 0.05% | Q2 2018 | Q1 2021 | 12 |
TRVN | Trevena, Inc. | 12 | 12 | 0.01% | 0.03% | 0.04% | Q3 2015 | Q2 2018 | 12 |
OPHT | Ophthotech Corporation | 12 | 12 | 0.01% | 0.02% | 0.05% | Q4 2013 | Q3 2016 | 12 |
IMDZ | Immune Design Corp. | 12 | 12 | 0.00% | 0.01% | 0.03% | Q2 2015 | Q1 2018 | 12 |
FMI | Foundation Medicine, Inc. | 11 | 1 | 0.00% | 0.01% | 0.05% | Q4 2013 | Q4 2016 | 12 |
GLMD | Galmed Pharmaceuticals... | 12 | 12 | 0.00% | 0.01% | 0.06% | Q2 2018 | Q1 2021 | 12 |
ALNY | Alnylam Pharmaceutical... | 12 | 12 | 0.00% | 0.01% | 0.01% | Q1 2014 | Q4 2016 | 12 |
ABUS | Arbutus Biopharma Corp... | 12 | 12 | 0.00% | 0.01% | 0.01% | Q3 2015 | Q2 2018 | 12 |
IMCR | Immunocore Holdings plc | 11 | 11 | 0.41% | 0.60% | 0.88% | Q1 2021 | Q3 2023 | 11 |
GILD | Gilead Sciences, Inc. | 11 | 11 | 0.20% | 0.47% | 1.26% | Q2 2013 | Q4 2015 | 11 |
KDNY | Chinook Therapeutics, ... | 11 | 11 | 0.04% | 0.20% | 0.40% | Q4 2020 | Q2 2023 | 11 |
TIL | Instil Bio, Inc. | 11 | 11 | 0.01% | 0.17% | 0.42% | Q1 2021 | Q3 2023 | 11 |
RVMD | Revolution Medicines, ... | 11 | 11 | 0.02% | 0.13% | 0.43% | Q1 2021 | Q3 2023 | 11 |
OMER | Omeros Corporation | 11 | 11 | 0.03% | 0.11% | 0.16% | Q3 2013 | Q1 2016 | 11 |
ALDR | Alder BioPharmaceutica... | 6 | 5 | 0.02% | 0.10% | 0.41% | Q2 2014 | Q2 2017 | 11 |
DSGN | Design Therapeutics, Inc. | 11 | 11 | 0.02% | 0.10% | 0.19% | Q1 2021 | Q3 2023 | 11 |
ALT | Altimmune, Inc. | 11 | 11 | 0.04% | 0.09% | 0.17% | Q2 2020 | Q4 2022 | 11 |
CFRX | ContraFect Corporation | 11 | 11 | 0.01% | 0.07% | 0.12% | Q3 2016 | Q1 2019 | 11 |
CNCE | Concert Pharmaceutical... | 11 | 11 | 0.02% | 0.06% | 0.09% | Q2 2014 | Q4 2016 | 11 |
ACHL | Achilles Therapeutics plc | 11 | 11 | 0.01% | 0.06% | 0.19% | Q1 2021 | Q3 2023 | 11 |
DSCO | Discovery Laboratories... | 11 | 11 | 0.01% | 0.05% | 0.12% | Q2 2013 | Q4 2015 | 11 |
EWTX | Edgewise Therapeutics,... | 11 | 11 | 0.02% | 0.03% | 0.07% | Q1 2021 | Q3 2023 | 11 |
Array BioPharma Inc. N... | 11 | 11 | 0.02% | 0.03% | 0.04% | Q1 2015 | Q3 2017 | 11 | |
JUNO | Juno Therapeutics, Inc. | 11 | 11 | 0.01% | 0.03% | 0.05% | Q4 2014 | Q2 2017 | 11 |
CMRX | Chimerix, Inc. | 11 | 11 | 0.01% | 0.02% | 0.07% | Q4 2014 | Q2 2017 | 11 |
ARAV | Aravive, Inc. | 8 | 3 | 0.00% | 0.02% | 0.04% | Q4 2018 | Q2 2023 | 11 |
ORTX | Orchard Therapeutics plc | 11 | 11 | 0.01% | 0.02% | 0.04% | Q4 2018 | Q2 2021 | 11 |
VKTX | Viking Therapeutics, Inc. | 11 | 11 | 0.01% | 0.02% | 0.05% | Q3 2018 | Q1 2021 | 11 |
CNST | Constellation Pharmace... | 11 | 11 | 0.00% | 0.01% | 0.03% | Q3 2018 | Q1 2021 | 11 |
PTN | Palatin Technologies, ... | 11 | 11 | 0.01% | 0.01% | 0.02% | Q4 2014 | Q2 2017 | 11 |
TCRR | TCR2 Therapeutics Inc. | 11 | 11 | 0.01% | 0.01% | 0.02% | Q3 2020 | Q1 2023 | 11 |
RCUS | Arcus Biosciences, Inc. | 11 | 11 | 0.01% | 0.01% | 0.01% | Q2 2018 | Q4 2020 | 11 |
RTTR | Ritter Pharmaceuticals... | 11 | 11 | 0.00% | 0.01% | 0.02% | Q2 2015 | Q4 2017 | 11 |
KZR | Kezar Life Sciences, Inc. | 11 | 11 | 0.00% | 0.01% | 0.01% | Q2 2020 | Q4 2022 | 11 |
ANAC | Anacor Pharmaceuticals... | 10 | 10 | 0.59% | 2.06% | 4.50% | Q4 2013 | Q1 2016 | 10 |
RPRX | Repros Therapeutics Inc. | 10 | 10 | 0.12% | 0.50% | 1.06% | Q2 2013 | Q3 2015 | 10 |
EXEL | Exelixis, Inc. | 10 | 10 | 0.08% | 0.33% | 0.57% | Q1 2016 | Q2 2018 | 10 |
FMTX | Forma Therapeutics Hol... | 10 | 10 | 0.08% | 0.23% | 0.41% | Q2 2020 | Q3 2022 | 10 |
VERV | Verve Therapeutics, Inc. | 10 | 10 | 0.11% | 0.21% | 0.38% | Q2 2021 | Q3 2023 | 10 |
AVTE | Aerovate Therapeutics,... | 10 | 10 | 0.10% | 0.19% | 0.35% | Q2 2021 | Q3 2023 | 10 |
VSTM | Verastem, Inc. | 10 | 10 | 0.06% | 0.18% | 0.38% | Q4 2020 | Q1 2023 | 10 |
ARWR | Arrowhead Research Corp. | 10 | 10 | 0.05% | 0.17% | 0.47% | Q3 2013 | Q4 2015 | 10 |
BMEA | Biomea Fusion, Inc. | 10 | 10 | 0.02% | 0.13% | 0.36% | Q2 2021 | Q3 2023 | 10 |
PTGX | Protagonist Therapeuti... | 10 | 10 | 0.03% | 0.10% | 0.16% | Q1 2019 | Q2 2021 | 10 |
PRQR | ProQR Therapeutics NV | 10 | 10 | 0.01% | 0.08% | 0.14% | Q3 2014 | Q4 2016 | 10 |
ISIS | Isis Pharmaceuticals, ... | 10 | 10 | 0.02% | 0.07% | 0.14% | Q2 2013 | Q3 2015 | 10 |
Invitae Corporation | 10 | 10 | 0.05% | 0.06% | 0.07% | Q3 2020 | Q4 2022 | 10 | |
MIRM | Mirum Pharmaceuticals,... | 9 | 1 | 0.02% | 0.04% | 0.06% | Q3 2019 | Q3 2023 | 10 |
KRTX | Karuna Therapeutics, Inc. | 10 | 10 | 0.02% | 0.04% | 0.05% | Q1 2020 | Q2 2022 | 10 |
GERN | Geron Corporation | 7 | 3 | 0.01% | 0.03% | 0.06% | Q2 2013 | Q3 2023 | 10 |
MSTX | Mast Therapeutics, Inc. | 9 | 1 | 0.01% | 0.02% | 0.03% | Q1 2014 | Q3 2016 | 10 |
OVID | Ovid Therapeutics Inc. | 6 | 4 | 0.00% | 0.02% | 0.03% | Q2 2017 | Q4 2020 | 10 |
PASG | Passage Bio, Inc. | 10 | 10 | 0.00% | 0.01% | 0.03% | Q1 2020 | Q2 2022 | 10 |
EVFM | Evofem Biosciences, Inc. | 10 | 10 | 0.00% | 0.01% | 0.02% | Q3 2019 | Q4 2021 | 10 |
TENX | Tenax Therapeutics, Inc. | 7 | 3 | 0.00% | 0.01% | 0.01% | Q2 2015 | Q4 2017 | 10 |
XOMA | XOMA Corporation | 9 | 9 | 0.44% | 1.19% | 2.18% | Q2 2013 | Q2 2015 | 9 |
DYAX | Dyax Corp. | 9 | 9 | 0.22% | 1.05% | 2.59% | Q4 2013 | Q4 2015 | 9 |
Medivation, Inc. 2.625... | 9 | 9 | 0.66% | 0.77% | 0.99% | Q2 2013 | Q2 2015 | 9 | |
AAAP | Advanced Accelerator A... | 9 | 9 | 0.04% | 0.48% | 1.23% | Q4 2015 | Q4 2017 | 9 |
CLVS | Clovis Oncology, Inc. | 5 | 4 | 0.12% | 0.32% | 0.70% | Q2 2013 | Q3 2015 | 9 |
Neurocrine Biosciences... | 8 | 1 | 0.11% | 0.28% | 0.52% | Q2 2018 | Q3 2020 | 9 | |
LEGN | Legend Biotech Corpora... | 9 | 9 | 0.01% | 0.24% | 0.56% | Q2 2020 | Q2 2022 | 9 |
KYTH | Kythera Biopharmaceuti... | 9 | 9 | 0.09% | 0.15% | 0.26% | Q2 2013 | Q2 2015 | 9 |
TLIS | Talis Biomedical Corpo... | 9 | 9 | 0.02% | 0.15% | 0.42% | Q1 2021 | Q1 2023 | 9 |
ECYT | Endocyte, Inc. | 5 | 4 | 0.02% | 0.11% | 0.30% | Q3 2015 | Q3 2018 | 9 |
THLD | Threshold Pharmaceutic... | 9 | 9 | 0.07% | 0.10% | 0.12% | Q3 2013 | Q3 2015 | 9 |
IDYA | IDEAYA Biosciences, Inc. | 5 | 4 | 0.00% | 0.08% | 0.18% | Q2 2019 | Q3 2023 | 9 |
ADHD | Alcobra Ltd. | 9 | 9 | 0.01% | 0.08% | 0.12% | Q4 2014 | Q4 2016 | 9 |
ZGNX | Zogenix, Inc. | 9 | 9 | 0.03% | 0.07% | 0.15% | Q2 2013 | Q2 2015 | 9 |
MNLO | Menlo Therapeutics Inc. | 9 | 9 | 0.01% | 0.05% | 0.22% | Q1 2018 | Q1 2020 | 9 |
GLYC | GlycoMimetics, Inc. | 9 | 9 | 0.02% | 0.05% | 0.08% | Q2 2016 | Q2 2018 | 9 |
TScan Therapeutics, Inc. | 9 | 9 | 0.02% | 0.04% | 0.06% | Q3 2021 | Q3 2023 | 9 | |
GNMX | Aevi Genomic Medicine,... | 9 | 9 | 0.02% | 0.04% | 0.07% | Q4 2016 | Q4 2018 | 9 |
SNTA | Synta Pharmaceuticals ... | 8 | 1 | 0.01% | 0.04% | 0.14% | Q2 2013 | Q2 2016 | 9 |
Tango Therapeutics, Inc. | 9 | 9 | 0.01% | 0.03% | 0.05% | Q3 2021 | Q3 2023 | 9 | |
RCPT | Receptos, Inc. | 9 | 9 | 0.01% | 0.03% | 0.04% | Q2 2013 | Q2 2015 | 9 |
GTHX | G1 Therapeutics, Inc. | 9 | 9 | 0.01% | 0.03% | 0.06% | Q1 2018 | Q1 2020 | 9 |
MCRB | Seres Therapeutics, Inc. | 9 | 9 | 0.01% | 0.03% | 0.05% | Q2 2015 | Q2 2017 | 9 |
SELB | Selecta Biosciences, Inc. | 9 | 9 | 0.01% | 0.03% | 0.05% | Q2 2016 | Q2 2018 | 9 |
BNR | Burning Rock Biotech L... | 9 | 9 | 0.00% | 0.02% | 0.03% | Q2 2020 | Q2 2022 | 9 |
ZIOP | ZIOPHARM Oncology, Inc. | 9 | 9 | 0.01% | 0.01% | 0.02% | Q2 2013 | Q2 2015 | 9 |
Sera Prognostics, Inc. | 9 | 9 | 0.00% | 0.01% | 0.04% | Q3 2021 | Q3 2023 | 9 | |
Surrozen, Inc. | 9 | 9 | 0.00% | 0.00% | 0.01% | Q3 2021 | Q3 2023 | 9 | |
PCYC | Pharmacyclics Inc. | 8 | 8 | 10.54% | 14.28% | 19.24% | Q2 2013 | Q1 2015 | 8 |
GEVA | Synageva Biopharma Corp. | 8 | 8 | 7.66% | 10.00% | 13.68% | Q2 2013 | Q1 2015 | 8 |
Salix Pharmaceuticals ... | 8 | 8 | 4.77% | 6.55% | 9.28% | Q2 2013 | Q1 2015 | 8 | |
PRNB | Principia Biopharma Inc. | 8 | 8 | 0.32% | 0.44% | 0.72% | Q3 2018 | Q2 2020 | 8 |
Entrada Therapeutics, ... | 8 | 8 | 0.25% | 0.39% | 0.50% | Q4 2021 | Q3 2023 | 8 | |
TVTX | Travere Therapeutics, ... | 8 | 8 | 0.01% | 0.29% | 0.53% | Q1 2021 | Q4 2022 | 8 |
BOLD | Audentes Therapeutics,... | 8 | 8 | 0.10% | 0.23% | 0.43% | Q1 2018 | Q4 2019 | 8 |
2seventy bio, Inc. | 8 | 8 | 0.06% | 0.14% | 0.20% | Q4 2021 | Q3 2023 | 8 | |
DICE Therapeutics, Inc. | 8 | 8 | 0.05% | 0.12% | 0.28% | Q3 2021 | Q2 2023 | 8 | |
SGYPQ | Synergy Pharmaceutical... | 7 | 1 | 0.00% | 0.11% | 0.22% | Q2 2013 | Q3 2015 | 8 |
ZGNX | Zogenix, Inc. | 8 | 8 | 0.02% | 0.10% | 0.22% | Q3 2015 | Q2 2017 | 8 |
NVAX | Novavax, Inc. | 8 | 8 | 0.02% | 0.08% | 0.13% | Q2 2020 | Q1 2022 | 8 |
DMTX | Dimension Therapeutics... | 8 | 8 | 0.02% | 0.07% | 0.12% | Q4 2015 | Q3 2017 | 8 |
HRMY | Harmony Biosciences Ho... | 8 | 8 | 0.02% | 0.03% | 0.05% | Q3 2020 | Q2 2022 | 8 |
OSUR | Orasure Technologies Inc. | 8 | 8 | 0.01% | 0.02% | 0.02% | Q2 2013 | Q1 2015 | 8 |
NVIV | InVivo Therapeutics Ho... | 8 | 8 | 0.00% | 0.02% | 0.03% | Q1 2016 | Q4 2017 | 8 |
ALDX | Aldeyra Therapeutics, ... | 8 | 8 | 0.01% | 0.01% | 0.01% | Q1 2015 | Q4 2016 | 8 |
LOGC | LogicBio Therapeutics,... | 8 | 8 | 0.00% | 0.01% | 0.01% | Q4 2020 | Q3 2022 | 8 |
INZY | Inozyme Pharma, Inc. | 8 | 8 | 0.00% | 0.01% | 0.01% | Q3 2020 | Q2 2022 | 8 |
Aptose Biosciences, Inc. | 6 | 2 | 0.00% | 0.01% | 0.03% | Q4 2014 | Q4 2016 | 8 | |
VINC | Vincerx Pharma, Inc. | 8 | 8 | 0.00% | 0.01% | 0.02% | Q3 2021 | Q2 2023 | 8 |
OYST | Oyster Point Pharma, Inc. | 8 | 8 | 0.00% | 0.01% | 0.01% | Q2 2020 | Q1 2022 | 8 |
FHTX | Foghorn Therapeutics Inc. | 8 | 8 | 0.00% | 0.00% | 0.01% | Q4 2021 | Q3 2023 | 8 |
ABBV | AbbVie Inc. | 7 | 7 | 1.04% | 7.14% | 9.33% | Q2 2015 | Q4 2016 | 7 |
AVNR | Avanir Pharmaceuticals | 7 | 7 | 0.26% | 1.74% | 6.66% | Q2 2013 | Q4 2014 | 7 |
MDVN | Medivation, Inc. | 4 | 3 | 0.16% | 0.28% | 0.39% | Q2 2013 | Q2 2016 | 7 |
Insmed Incorporated | 7 | 7 | 0.12% | 0.19% | 0.24% | Q2 2021 | Q4 2022 | 7 | |
CMTA | Clementia Pharmaceutic... | 7 | 7 | 0.03% | 0.19% | 0.62% | Q3 2017 | Q1 2019 | 7 |
ADPT | Adaptive Biotechnologi... | 7 | 7 | 0.08% | 0.17% | 0.38% | Q2 2019 | Q4 2020 | 7 |
SLXP | Salix Pharmaceuticals,... | 7 | 7 | 0.00% | 0.12% | 0.74% | Q2 2013 | Q4 2014 | 7 |
QLTI | QLT, Inc. | 7 | 7 | 0.06% | 0.10% | 0.13% | Q2 2013 | Q4 2014 | 7 |
BCAB | BioAtla, Inc. | 7 | 7 | 0.01% | 0.10% | 0.18% | Q4 2020 | Q2 2022 | 7 |
FGEN | FibroGen, Inc. | 7 | 7 | 0.00% | 0.09% | 0.27% | Q4 2021 | Q2 2023 | 7 |
FREQ | Frequency Therapeutics... | 7 | 7 | 0.00% | 0.08% | 0.13% | Q4 2019 | Q2 2021 | 7 |
OTIC | Otonomy, Inc. | 7 | 7 | 0.02% | 0.07% | 0.11% | Q1 2021 | Q3 2022 | 7 |
TKMR | Tekmire Pharmaceutical... | 7 | 7 | 0.02% | 0.07% | 0.13% | Q4 2013 | Q2 2015 | 7 |
SBTX | Silverback Therapeutic... | 4 | 3 | 0.03% | 0.06% | 0.10% | Q4 2020 | Q3 2023 | 7 |
SNSS | Sunesis Pharmaceutical... | 7 | 7 | 0.02% | 0.05% | 0.08% | Q4 2014 | Q2 2016 | 7 |
VTAE | Vitae Pharmaceuticals,... | 7 | 7 | 0.02% | 0.05% | 0.12% | Q1 2015 | Q3 2016 | 7 |
MRKR | Marker Therapeutics, Inc. | 7 | 7 | 0.00% | 0.04% | 0.08% | Q4 2018 | Q2 2020 | 7 |
CYT | Cyteir Therapeutics, Inc. | 7 | 7 | 0.02% | 0.04% | 0.08% | Q2 2021 | Q4 2022 | 7 |
BOTA | Biota Pharmaceuticals,... | 7 | 7 | 0.02% | 0.04% | 0.09% | Q4 2013 | Q2 2015 | 7 |
INOTEK Technologies Corp. | 7 | 7 | 0.02% | 0.04% | 0.06% | Q3 2016 | Q1 2018 | 7 | |
ISEE | IVERIC bio, Inc. | 7 | 7 | 0.01% | 0.03% | 0.04% | Q4 2019 | Q2 2021 | 7 |
NBRV | Nabriva Therapeutics AG | 7 | 7 | 0.02% | 0.03% | 0.03% | Q3 2015 | Q1 2017 | 7 |
FOLD | Amicus Therapeutics | 7 | 7 | 0.01% | 0.02% | 0.04% | Q2 2013 | Q4 2014 | 7 |
GMDA | Gamida Cell Ltd. | 7 | 7 | 0.01% | 0.02% | 0.05% | Q2 2020 | Q4 2021 | 7 |
TSRO | Tesaro Inc. | 7 | 7 | 0.01% | 0.01% | 0.02% | Q2 2013 | Q4 2014 | 7 |
RTTR | Ritter Pharmaceuticals... | 7 | 7 | 0.00% | 0.00% | 0.01% | Q1 2018 | Q3 2019 | 7 |
Incyte Genomics Notes... | 6 | 6 | 2.84% | 3.38% | 4.20% | Q1 2014 | Q2 2015 | 6 | |
AVXS | AveXis, Inc. | 6 | 6 | 0.15% | 0.58% | 1.22% | Q4 2016 | Q1 2018 | 6 |
AEGR | Aegerion Pharmaceutica... | 5 | 1 | 0.00% | 0.52% | 1.16% | Q2 2013 | Q1 2015 | 6 |
Novavax, Inc. | 6 | 6 | 0.32% | 0.39% | 0.52% | Q1 2017 | Q2 2018 | 6 | |
Salix Pharmaceuticals ... | 6 | 6 | 0.28% | 0.34% | 0.46% | Q4 2013 | Q1 2015 | 6 | |
Sarepta Therapeutics, ... | 6 | 6 | 0.05% | 0.17% | 0.22% | Q1 2021 | Q2 2022 | 6 | |
AMBI | Ambit Biosciences Corp. | 6 | 6 | 0.06% | 0.12% | 0.21% | Q2 2013 | Q3 2014 | 6 |
RLMD | Relmada Therapeutics, ... | 6 | 6 | 0.01% | 0.06% | 0.12% | Q2 2021 | Q3 2022 | 6 |
VERA | Vera Therapeutics, Inc. | 6 | 6 | 0.01% | 0.03% | 0.05% | Q1 2022 | Q2 2023 | 6 |
VOR | Vor Biopharma Inc. | 6 | 6 | 0.01% | 0.03% | 0.06% | Q2 2022 | Q3 2023 | 6 |
FTSV | Forty Seven, Inc. | 6 | 6 | 0.01% | 0.02% | 0.03% | Q2 2018 | Q3 2019 | 6 |
TNXP | Tonix Pharmaceuticals ... | 6 | 6 | 0.02% | 0.02% | 0.03% | Q1 2017 | Q2 2018 | 6 |
CRBP | Corbus Pharmaceuticals... | 3 | 3 | 0.01% | 0.02% | 0.04% | Q4 2016 | Q2 2018 | 6 |
YMAB | Y-mAbs Therapeutics, Inc. | 6 | 6 | 0.02% | 0.02% | 0.03% | Q3 2018 | Q4 2019 | 6 |
MRNS | Marinus Pharmaceutical... | 6 | 6 | 0.01% | 0.02% | 0.02% | Q3 2014 | Q4 2015 | 6 |
DNAI | ProNAi Therapeutics, Inc. | 6 | 6 | 0.00% | 0.01% | 0.04% | Q3 2015 | Q4 2016 | 6 |
NEXI | NexImmune, Inc. | 6 | 6 | 0.00% | 0.01% | 0.02% | Q1 2021 | Q2 2022 | 6 |
JNCE | Jounce Therapeutics, Inc. | 6 | 6 | 0.01% | 0.01% | 0.02% | Q1 2017 | Q2 2018 | 6 |
LIFE | aTyr Pharma, Inc. | 6 | 6 | 0.00% | 0.01% | 0.02% | Q3 2021 | Q4 2022 | 6 |
Intermune Inc Notes 2.... | 5 | 5 | 0.79% | 1.12% | 1.73% | Q2 2013 | Q2 2014 | 5 | |
Clovis Oncology, Inc. ... | 5 | 5 | 0.54% | 1.00% | 1.99% | Q3 2015 | Q3 2016 | 5 | |
QCOR | Questcor Pharmaceutica... | 5 | 5 | 0.28% | 0.50% | 0.60% | Q2 2013 | Q2 2014 | 5 |
Intermune Inc Notes 5%... | 5 | 5 | 0.28% | 0.36% | 0.49% | Q2 2013 | Q2 2014 | 5 | |
ADCT | ADC Therapeutics SA | 5 | 5 | 0.15% | 0.21% | 0.35% | Q2 2020 | Q2 2021 | 5 |
BCYC | Bicycle Therapeutics plc | 5 | 5 | 0.10% | 0.12% | 0.15% | Q3 2022 | Q3 2023 | 5 |
LBIO | Lion Biotechnologies, ... | 5 | 5 | 0.06% | 0.11% | 0.15% | Q1 2015 | Q1 2016 | 5 |
STOK | Stoke Therapeutics, Inc. | 5 | 5 | 0.03% | 0.07% | 0.13% | Q3 2022 | Q3 2023 | 5 |
Surrozen, Inc. | 5 | 5 | 0.03% | 0.06% | 0.08% | Q3 2021 | Q3 2022 | 5 | |
Aadi Bioscience, Inc. | 5 | 5 | 0.03% | 0.05% | 0.09% | Q3 2022 | Q3 2023 | 5 | |
CNTA | Centessa Pharmaceutica... | 5 | 5 | 0.03% | 0.05% | 0.08% | Q2 2021 | Q2 2022 | 5 |
MREO | Mereo BioPharma Group PLC | 4 | 1 | 0.00% | 0.05% | 0.10% | Q4 2020 | Q2 2023 | 5 |
NLNK | NewLink Genetics Corpo... | 5 | 5 | 0.02% | 0.05% | 0.08% | Q2 2017 | Q2 2018 | 5 |
PNT | POINT Biopharma Global... | 5 | 5 | 0.01% | 0.05% | 0.06% | Q3 2022 | Q3 2023 | 5 |
Nabriva Therapeutics plc | 5 | 5 | 0.02% | 0.04% | 0.06% | Q2 2017 | Q2 2018 | 5 | |
CRIS | Curis, Inc. | 5 | 5 | 0.03% | 0.04% | 0.05% | Q2 2015 | Q2 2016 | 5 |
IPSC | Century Therapeutics, ... | 5 | 5 | 0.01% | 0.02% | 0.04% | Q3 2022 | Q3 2023 | 5 |
IONS | Ionis Pharmaceuticals,... | 5 | 5 | 0.01% | 0.02% | 0.03% | Q4 2015 | Q4 2016 | 5 |
CHMA | Chiasma, Inc. | 5 | 5 | 0.01% | 0.02% | 0.03% | Q2 2020 | Q2 2021 | 5 |
NKTX | Nkarta, Inc. | 5 | 5 | 0.00% | 0.02% | 0.03% | Q2 2022 | Q2 2023 | 5 |
HARP | Harpoon Therapeutics, ... | 5 | 5 | 0.01% | 0.02% | 0.02% | Q1 2019 | Q1 2020 | 5 |
PMVP | PMV Pharmaceuticals, Inc. | 5 | 5 | 0.01% | 0.01% | 0.02% | Q3 2022 | Q3 2023 | 5 |
SNDX | Syndax Pharmaceuticals... | 5 | 5 | 0.01% | 0.01% | 0.02% | Q3 2021 | Q3 2022 | 5 |
CTMX | CytomX Therapeutics, Inc. | 5 | 5 | 0.00% | 0.01% | 0.02% | Q1 2019 | Q1 2020 | 5 |
AQST | Aquestive Therapeutics... | 5 | 5 | 0.00% | 0.01% | 0.01% | Q3 2018 | Q3 2019 | 5 |
GNFT | Genfit SA | 5 | 5 | 0.00% | 0.00% | 0.00% | Q1 2020 | Q1 2021 | 5 |
Auxilium 1.5% 7/15/2018 | 4 | 4 | 1.28% | 1.51% | 1.74% | Q2 2013 | Q1 2014 | 4 | |
EXAS | Exact Sciences Corpora... | 4 | 4 | 0.66% | 0.85% | 1.27% | Q4 2019 | Q3 2020 | 4 |
ICPT | Intercept Pharmaceutic... | 4 | 4 | 0.35% | 0.55% | 1.08% | Q2 2013 | Q1 2014 | 4 |
Roivant Sciences Ltd. | 4 | 4 | 0.03% | 0.39% | 0.80% | Q4 2022 | Q3 2023 | 4 | |
SWTX | SpringWorks Therapeuti... | 4 | 4 | 0.24% | 0.37% | 0.46% | Q4 2022 | Q3 2023 | 4 |
ERYP | ERYTECH Pharma S.A. | 4 | 4 | 0.06% | 0.36% | 0.59% | Q4 2017 | Q3 2018 | 4 |
CHTP | Chelsea Therapeutics | 4 | 4 | 0.22% | 0.32% | 0.47% | Q2 2013 | Q1 2014 | 4 |
Exelixis, Inc. Notes 4... | 4 | 4 | 0.19% | 0.23% | 0.31% | Q3 2015 | Q2 2016 | 4 | |
LIFE | aTyr Pharma, Inc. | 4 | 4 | 0.09% | 0.22% | 0.38% | Q2 2015 | Q1 2016 | 4 |
SLDB | Solid Biosciences Inc. | 4 | 4 | 0.04% | 0.13% | 0.18% | Q1 2018 | Q4 2018 | 4 |
PTLA | Portola Pharmaceutical... | 4 | 4 | 0.06% | 0.11% | 0.19% | Q2 2013 | Q1 2014 | 4 |
PRTA | Prothena Corp. PLC | 4 | 4 | 0.09% | 0.11% | 0.13% | Q2 2013 | Q1 2014 | 4 |
Prime Medicine, Inc. | 4 | 4 | 0.06% | 0.08% | 0.12% | Q4 2022 | Q3 2023 | 4 | |
ARWR | Arrowhead Pharmaceutic... | 3 | 1 | 0.04% | 0.07% | 0.12% | Q1 2016 | Q3 2018 | 4 |
SMMT | Summit Therapeutics Inc. | 4 | 4 | 0.03% | 0.06% | 0.09% | Q4 2022 | Q3 2023 | 4 |
UROV | Urovant Sciences Ltd. | 4 | 4 | 0.04% | 0.05% | 0.08% | Q4 2019 | Q3 2020 | 4 |
RNA | Avidity Biosciences, Inc. | 4 | 4 | 0.01% | 0.05% | 0.08% | Q4 2022 | Q3 2023 | 4 |
CLTX | Celsus Therapeutics | 4 | 4 | 0.03% | 0.05% | 0.06% | Q1 2014 | Q4 2014 | 4 |
VTUS | Ventrus Biosciences, Inc. | 4 | 4 | 0.01% | 0.04% | 0.06% | Q2 2013 | Q1 2014 | 4 |
MDGN | Medgenics, Inc. | 4 | 4 | 0.04% | 0.04% | 0.05% | Q4 2015 | Q3 2016 | 4 |
TTPH | Tetraphase Pharmaceuti... | 4 | 4 | 0.02% | 0.04% | 0.05% | Q3 2017 | Q2 2018 | 4 |
NERV | Minerva Neurosciences,... | 3 | 1 | 0.03% | 0.04% | 0.05% | Q2 2016 | Q1 2020 | 4 |
FATE | Fate Therapeutics, Inc. | 4 | 4 | 0.01% | 0.04% | 0.05% | Q3 2022 | Q2 2023 | 4 |
LPCN | Lipocine Inc. | 4 | 4 | 0.03% | 0.03% | 0.04% | Q2 2014 | Q1 2015 | 4 |
CMPX | Compass Therapeutics, ... | 4 | 4 | 0.02% | 0.03% | 0.05% | Q4 2022 | Q3 2023 | 4 |
ATRA | Atara Biotherapeutics,... | 4 | 4 | 0.01% | 0.02% | 0.03% | Q2 2022 | Q1 2023 | 4 |
PRAX | Praxis Precision Medic... | 4 | 4 | 0.01% | 0.02% | 0.03% | Q4 2022 | Q3 2023 | 4 |
MTNB | Matinas BioPharma Hold... | 4 | 4 | 0.01% | 0.02% | 0.03% | Q3 2019 | Q2 2020 | 4 |
SRRA | Sierra Oncology, Inc. | 4 | 4 | 0.01% | 0.01% | 0.02% | Q4 2018 | Q3 2019 | 4 |
PCVX | Vaxcyte, Inc. | 4 | 4 | 0.01% | 0.01% | 0.01% | Q4 2022 | Q3 2023 | 4 |
Kala Pharmaceuticals, ... | 4 | 4 | 0.01% | 0.01% | 0.02% | Q4 2022 | Q3 2023 | 4 | |
OHRP | Ohr Pharmaceuticals, Inc. | 4 | 4 | 0.01% | 0.01% | 0.02% | Q1 2015 | Q4 2015 | 4 |
DRNA | Dicerna Pharmaceutical... | 4 | 4 | 0.01% | 0.01% | 0.01% | Q1 2020 | Q4 2020 | 4 |
TTOO | T2 Biosystems, Inc. | 4 | 4 | 0.00% | 0.00% | 0.01% | Q3 2017 | Q2 2018 | 4 |
WINT | Windtree Therapeutics,... | 4 | 4 | 0.00% | 0.00% | 0.01% | Q2 2016 | Q1 2017 | 4 |
Incyte Genomics Notes... | 3 | 3 | 3.28% | 7.00% | 9.78% | Q2 2013 | Q4 2013 | 3 | |
ITMN | Intermune Inc. | 3 | 3 | 0.03% | 1.48% | 2.55% | Q4 2013 | Q2 2014 | 3 |
Apellis Pharmaceutical... | 3 | 3 | 0.12% | 0.20% | 0.25% | Q2 2021 | Q4 2021 | 3 | |
URGN | UroGen Pharma Ltd. | 3 | 3 | 0.07% | 0.11% | 0.15% | Q3 2019 | Q1 2020 | 3 |
Tricida, Inc. | 3 | 3 | 0.07% | 0.11% | 0.14% | Q2 2021 | Q4 2021 | 3 | |
Corsicanto Ltd. 3.5% 1... | 3 | 3 | 0.04% | 0.11% | 0.16% | Q4 2015 | Q2 2016 | 3 | |
GLUE | Monte Rosa Therapeutic... | 3 | 3 | 0.02% | 0.09% | 0.14% | Q1 2023 | Q3 2023 | 3 |
ZFGN | Zafgen, Inc. | 3 | 3 | 0.03% | 0.08% | 0.12% | Q1 2015 | Q3 2015 | 3 |
PBYI | Puma Biotechnology | 3 | 3 | 0.04% | 0.06% | 0.08% | Q2 2013 | Q4 2013 | 3 |
CLDN | Celladon Corp | 3 | 3 | 0.05% | 0.06% | 0.08% | Q3 2014 | Q1 2015 | 3 |
VERU | Veru Inc. | 3 | 3 | 0.01% | 0.06% | 0.12% | Q3 2022 | Q1 2023 | 3 |
RLAY | Relay Therapeutics, Inc. | 3 | 3 | 0.02% | 0.06% | 0.08% | Q1 2023 | Q3 2023 | 3 |
GALT | Galectin Therapeutics ... | 3 | 3 | 0.01% | 0.05% | 0.10% | Q4 2013 | Q2 2014 | 3 |
IMMU | Immunomedics, Inc. | 3 | 3 | 0.03% | 0.05% | 0.08% | Q1 2020 | Q3 2020 | 3 |
LGND | Ligand Pharmaceuticals... | 3 | 3 | 0.04% | 0.05% | 0.05% | Q2 2013 | Q4 2013 | 3 |
SANA | Sana Biotechnology, Inc. | 3 | 3 | 0.04% | 0.05% | 0.07% | Q1 2023 | Q3 2023 | 3 |
MNTA | Momenta Pharmaceutical... | 3 | 3 | 0.05% | 0.05% | 0.05% | Q1 2018 | Q3 2018 | 3 |
VXRT | Vaxart, Inc. | 3 | 3 | 0.03% | 0.05% | 0.06% | Q2 2020 | Q4 2020 | 3 |
SRPT | Sarepta Therapeutics, ... | 2 | 1 | 0.02% | 0.04% | 0.06% | Q1 2021 | Q1 2022 | 3 |
NXTC | NextCure, Inc. | 3 | 3 | 0.02% | 0.03% | 0.04% | Q2 2019 | Q4 2019 | 3 |
KURA | Kura Oncology, Inc. | 3 | 3 | 0.02% | 0.02% | 0.02% | Q3 2021 | Q1 2022 | 3 |
MRSN | Mersana Therapeutics, ... | 3 | 3 | 0.01% | 0.02% | 0.04% | Q1 2023 | Q3 2023 | 3 |
BLPH | Bellerophon Therapeuti... | 3 | 3 | 0.02% | 0.02% | 0.03% | Q1 2015 | Q3 2015 | 3 |
SCYX | SCYNEXIS, Inc. | 3 | 3 | 0.01% | 0.01% | 0.02% | Q2 2016 | Q4 2016 | 3 |
APLT | Applied Therapeutics, ... | 3 | 3 | 0.00% | 0.01% | 0.01% | Q1 2020 | Q3 2020 | 3 |
BPMX | BioPharmX Corporation | 3 | 3 | 0.00% | 0.00% | 0.00% | Q1 2017 | Q3 2017 | 3 |
VPHM | Viropharma Inc. | 2 | 2 | 3.12% | 3.98% | 4.83% | Q2 2013 | Q3 2013 | 2 |
Anacor Pharmaceuticals... | 2 | 2 | 0.80% | 1.03% | 1.26% | Q4 2015 | Q1 2016 | 2 | |
ABLX | Ablynx NV | 2 | 2 | 0.90% | 0.95% | 1.01% | Q4 2017 | Q1 2018 | 2 |
XenoPort, Inc. Notes 2... | 2 | 2 | 0.77% | 0.90% | 1.03% | Q1 2016 | Q2 2016 | 2 | |
Invitae Corporation | 2 | 2 | 0.75% | 0.77% | 0.78% | Q2 2023 | Q3 2023 | 2 | |
ARIA | Ariad Pharmaceuticals ... | 2 | 2 | 0.35% | 0.43% | 0.50% | Q2 2013 | Q3 2013 | 2 |
NKTR | Nektar Therapeutics | 2 | 2 | 0.09% | 0.17% | 0.25% | Q4 2017 | Q1 2018 | 2 |
MNKKQ | Mallinckrodt PUB LTD CO | 2 | 2 | 0.05% | 0.14% | 0.23% | Q3 2014 | Q4 2014 | 2 |
CinCor Pharma, Inc. | 2 | 2 | 0.06% | 0.12% | 0.17% | Q3 2022 | Q4 2022 | 2 | |
Anacor Pharmaceuticals | 2 | 2 | 0.10% | 0.11% | 0.13% | Q2 2013 | Q3 2013 | 2 | |
Corsicanto II Designat... | 2 | 2 | 0.08% | 0.09% | 0.09% | Q1 2018 | Q2 2018 | 2 | |
COGT | Cogent Biosciences, Inc. | 2 | 2 | 0.07% | 0.07% | 0.07% | Q2 2023 | Q3 2023 | 2 |
DAWN | Day One Biopharmaceuti... | 2 | 2 | 0.07% | 0.07% | 0.07% | Q2 2023 | Q3 2023 | 2 |
MEIP | MEI Pharma, Inc. | 2 | 2 | 0.06% | 0.06% | 0.07% | Q2 2013 | Q3 2013 | 2 |
RGDO | Regado | 2 | 2 | 0.03% | 0.05% | 0.06% | Q1 2014 | Q2 2014 | 2 |
UTHR | United Therapeutics Corp. | 2 | 2 | 0.03% | 0.05% | 0.06% | Q3 2013 | Q4 2013 | 2 |
ALLO | Allogene Therapeutics,... | 2 | 2 | 0.04% | 0.04% | 0.04% | Q1 2023 | Q2 2023 | 2 |
MIST | Milestone Pharmaceutic... | 2 | 2 | 0.03% | 0.04% | 0.05% | Q2 2019 | Q3 2019 | 2 |
BIIB | Biogen Inc. | 2 | 2 | 0.04% | 0.04% | 0.05% | Q4 2016 | Q1 2017 | 2 |
XBIT | XBiotech Inc. | 2 | 2 | 0.02% | 0.03% | 0.04% | Q2 2019 | Q3 2019 | 2 |
MLND | Millendo Therapeutics,... | 2 | 2 | 0.03% | 0.03% | 0.03% | Q4 2019 | Q1 2020 | 2 |
KRON | Kronos Bio, Inc. | 2 | 2 | 0.01% | 0.02% | 0.03% | Q3 2022 | Q4 2022 | 2 |
GRCL | Gracell Biotechnologie... | 2 | 2 | 0.02% | 0.02% | 0.02% | Q2 2023 | Q3 2023 | 2 |
Talis Biomedical Corpo... | 2 | 2 | 0.02% | 0.02% | 0.02% | Q2 2023 | Q3 2023 | 2 | |
CYCN | Cyclerion Therapeutics... | 2 | 2 | 0.02% | 0.02% | 0.02% | Q2 2019 | Q3 2019 | 2 |
Leap Therapeutics, Inc. | 2 | 2 | 0.01% | 0.02% | 0.02% | Q2 2023 | Q3 2023 | 2 | |
DOVA | Dova Pharmaceuticals, ... | 2 | 2 | 0.01% | 0.01% | 0.02% | Q2 2019 | Q3 2019 | 2 |
CLCD | CoLucid Pharmaceutical... | 2 | 2 | 0.01% | 0.01% | 0.01% | Q3 2016 | Q4 2016 | 2 |
ISR | Perspective Therapeuti... | 2 | 2 | 0.01% | 0.01% | 0.01% | Q2 2023 | Q3 2023 | 2 |
ARYA | ARYA Sciences Acquisit... | 2 | 2 | 0.01% | 0.01% | 0.01% | Q1 2020 | Q2 2020 | 2 |
BIOD | Biodel Inc. | 1 | 1 | 0.00% | 0.01% | 0.02% | Q2 2013 | Q1 2015 | 2 |
CBST | Cubist Pharmaceuticals... | 2 | 2 | 0.01% | 0.01% | 0.01% | Q2 2013 | Q3 2013 | 2 |
BIVV | Bioverativ Inc. | 2 | 2 | 0.00% | 0.00% | 0.00% | Q1 2017 | Q2 2017 | 2 |
AVNR | Avanir Pharmaceuticals... | 1 | 1 | 1.40% | 1.40% | 1.40% | Q3 2014 | Q3 2014 | 1 |
Corsicanto II Designat... | 1 | 1 | 0.28% | 0.28% | 0.28% | Q3 2018 | Q3 2018 | 1 | |
Salix Pharmaceuticals ... | 1 | 1 | 0.19% | 0.19% | 0.19% | Q2 2014 | Q2 2014 | 1 | |
THLD | Threshold Pharma | 1 | 1 | 0.17% | 0.17% | 0.17% | Q2 2013 | Q2 2013 | 1 |
TRGT | Targacept | 1 | 1 | 0.16% | 0.16% | 0.16% | Q3 2013 | Q3 2013 | 1 |
Infinity Pharmaceutica... | 1 | 1 | 0.12% | 0.12% | 0.12% | Q4 2013 | Q4 2013 | 1 | |
Neurocrine Biosciences... | 1 | 1 | 0.11% | 0.11% | 0.11% | Q3 2018 | Q3 2018 | 1 | |
BioMarin Pharmaceutica... | 1 | 1 | 0.10% | 0.10% | 0.10% | Q3 2018 | Q3 2018 | 1 | |
IMVT | Immunovant, Inc. | 1 | 1 | 0.09% | 0.09% | 0.09% | Q3 2023 | Q3 2023 | 1 |
BioMarin Pharmaceutica... | 1 | 1 | 0.08% | 0.08% | 0.08% | Q3 2018 | Q3 2018 | 1 | |
BPMC | Blueprint Medicines Co... | 1 | 1 | 0.08% | 0.08% | 0.08% | Q1 2023 | Q1 2023 | 1 |
Zymeworks Inc. | 1 | 1 | 0.08% | 0.08% | 0.08% | Q4 2022 | Q4 2022 | 1 | |
Verastem, Inc. | 1 | 1 | 0.06% | 0.06% | 0.06% | Q2 2023 | Q2 2023 | 1 | |
RTRX | Retrophin Inc. | 1 | 1 | 0.05% | 0.05% | 0.05% | Q1 2014 | Q1 2014 | 1 |
ARVN | Arvinas, Inc. | 1 | 1 | 0.05% | 0.05% | 0.05% | Q3 2023 | Q3 2023 | 1 |
TSHA | Taysha Gene Therapies,... | 1 | 1 | 0.05% | 0.05% | 0.05% | Q3 2023 | Q3 2023 | 1 |
FURX | Furiex Pharmaceuticals... | 1 | 1 | 0.04% | 0.04% | 0.04% | Q1 2014 | Q1 2014 | 1 |
TTHI | Transition Therapeutic... | 1 | 1 | 0.04% | 0.04% | 0.04% | Q1 2015 | Q1 2015 | 1 |
Sagimet Biosciences Inc. | 1 | 1 | 0.04% | 0.04% | 0.04% | Q3 2023 | Q3 2023 | 1 | |
Biohaven Ltd. | 1 | 1 | 0.04% | 0.04% | 0.04% | Q4 2022 | Q4 2022 | 1 | |
VYGR | Voyager Therapeutics, ... | 1 | 1 | 0.04% | 0.04% | 0.04% | Q3 2017 | Q3 2017 | 1 |
ARQL | Arqule Inc. | 1 | 1 | 0.04% | 0.04% | 0.04% | Q2 2013 | Q2 2013 | 1 |
SESN | Sesen Bio, Inc. | 1 | 1 | 0.04% | 0.04% | 0.04% | Q2 2018 | Q2 2018 | 1 |
Invitae Corporation | 1 | 1 | 0.04% | 0.04% | 0.04% | Q3 2023 | Q3 2023 | 1 | |
MORF | Morphic Holding, Inc. | 1 | 1 | 0.03% | 0.03% | 0.03% | Q3 2023 | Q3 2023 | 1 |
TARA | ArTara Therapeutics, Inc. | 1 | 1 | 0.03% | 0.03% | 0.03% | Q1 2020 | Q1 2020 | 1 |
Neoleukin Therapeutics... | 1 | 1 | 0.03% | 0.03% | 0.03% | Q3 2023 | Q3 2023 | 1 | |
CELC | Celcuity Inc. | 1 | 1 | 0.03% | 0.03% | 0.03% | Q3 2023 | Q3 2023 | 1 |
EIGR | Eiger BioPharmaceutica... | 1 | 1 | 0.03% | 0.03% | 0.03% | Q3 2022 | Q3 2022 | 1 |
AMYT | Amryt Pharma plc | 1 | 1 | 0.03% | 0.03% | 0.03% | Q3 2021 | Q3 2021 | 1 |
Mast Therapeutics, Inc. | 1 | 1 | 0.02% | 0.02% | 0.02% | Q2 2014 | Q2 2014 | 1 | |
FLXN | Flexion Therapeutics, ... | 1 | 1 | 0.02% | 0.02% | 0.02% | Q4 2015 | Q4 2015 | 1 |
ASPX | Auspex Pharmaceuticals... | 1 | 1 | 0.02% | 0.02% | 0.02% | Q1 2015 | Q1 2015 | 1 |
AUXL | Auxilium Pharmaceutica... | 1 | 1 | 0.02% | 0.02% | 0.02% | Q1 2014 | Q1 2014 | 1 |
GOSS | Gossamer Bio, Inc. | 1 | 1 | 0.02% | 0.02% | 0.02% | Q4 2020 | Q4 2020 | 1 |
LPTN | Lpath Inc. | 1 | 1 | 0.02% | 0.02% | 0.02% | Q2 2013 | Q2 2013 | 1 |
Evofem Biosciences, Inc. | 1 | 1 | 0.02% | 0.02% | 0.02% | Q2 2022 | Q2 2022 | 1 | |
ALRN | Aileron Therapeutics, ... | 1 | 1 | 0.01% | 0.01% | 0.01% | Q2 2019 | Q2 2019 | 1 |
DSCO | Discovery Laboratories... | 1 | 1 | 0.00% | 0.00% | 0.00% | Q1 2016 | Q1 2016 | 1 |
AST | Asterias Biotherapeuti... | 1 | 1 | 0.00% | 0.00% | 0.00% | Q4 2014 | Q4 2014 | 1 |
ARDM | Aradigm Corp. | 1 | 1 | 0.00% | 0.00% | 0.00% | Q2 2013 | Q2 2013 | 1 |
SNSS | Sunesis Pharmaceutical... | 1 | 1 | 0.00% | 0.00% | 0.00% | Q4 2020 | Q4 2020 | 1 |
Download |
The securities at the top of the list , including Incyte Corporation, ACADIA Pharmaceuticals Inc., and Biomarin Pharmaceuticals Inc., are the highest-conviction holdings of Baker Brothers Advisors.
The conviction is calculated by counting the number of quarters a security has been reported by Baker Brothers Advisors. The higher the number, the higher the conviction and longer the holding period.
This page lists all the securities that Baker Brothers Advisors owns currently or has owned in the past.